title: Outcomes of HIV-infected patients treated for recurrent tuberculosis with the standard retreatment regimen.
abstract: METHODS
  The Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes (the GHESKIO AIDS and TB Center) in Port-au-Prince, Haiti.
  
  
  OBJECTIVE
  To measure the effectiveness of the standard TB retreatment regimen (2HRZES/1HRZE/5HRE) in human immunodeficiency virus (HIV)  infected adults.
  
  
  METHODS
  Cohort study.
  
  
  RESULTS
  Of 1318 HIV-infected patients with access to antiretroviral therapy following World Health Organization guidelines, 56 were diagnosed with recurrent pulmonary TB and retreated with the standard retreatment regimen: 10 patients (18%) died  during retreatment, 3 (5%) defaulted, and 2 (4%) failed treatment. Forty-one patients (73%) achieved retreatment 'success' (cure, treatment completed). Of these, 8 (20%) died during follow-up, 5 (12%) were lost, and 5 (12%) had a second recurrence of TB. Only 26 (46%) of the 56  patients remained alive, in care, and TB-free after a median of 36 months of follow-up.
  
  
  CONCLUSIONS
  HIV-infected patients treated for recurrent TB with the standard retreatment regimen have high mortality and poor long-term outcomes.
authors.affiliation: Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO), Port au Prince, Haiti. jolionmcgreevy@gmail.com
authors.forename: J
authors.initials: J
authors.lastname: McGreevy
authors.forename: M A
authors.initials: MA
authors.lastname: Jean Juste
authors.forename: P
authors.initials: P
authors.lastname: Severe
authors.forename: S
authors.initials: S
authors.lastname: Collins
authors.forename: S
authors.initials: S
authors.lastname: Koenig
authors.forename: J W
authors.initials: JW
authors.lastname: Pape
authors.forename: D W
authors.initials: DW
authors.lastname: Fitzgerald
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D015331:Cohort Studies; D060085:Coinfection; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D006205:Haiti / Q000453:epidemiology; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D017410:Practice Guidelines as Topic; D016016:Proportional Hazards Models; D012008:Recurrence; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality
chemical_list: D019380:Anti-HIV Agents; D000995:Antitubercular Agents